Repare Therapeutics Inc (RPTX)

Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating ... - StockTitan

StockTitan

Repare Therapeutics shareholders approve key proposals By Investing.com - Investing.com Australia

Investing.com Australia

Repare Therapeutics shareholders approve key proposals By Investing.com - Investing.com

Investing.com

BeiGene, Ltd. (BGNE) Soars 20.6%: Is Further Upside Left in the Stock? - Yahoo New Zealand News

Yahoo New Zealand News

Repare Therapeutics shareholders approve key proposals - Investing.com India

Investing.com India

Hedge funds own 26% of Repare Therapeutics Inc. (NASDAQ:RPTX) shares but private equity firms control 36% of the ... - Yahoo New Zealand News

Yahoo New Zealand News

Repare Therapeutics Inc. (NASDAQ:RPTX) to Post Q2 2024 Earnings of ($0.86) Per Share, Capital One Financial ... - MarketBeat

MarketBeat

Q2 2024 Earnings Estimate for Repare Therapeutics Inc. (NASDAQ:RPTX) Issued By Capital One Financial - Defense World

Defense World

Capital One Financial Weighs in on Repare Therapeutics Inc.'s FY2028 Earnings (NASDAQ:RPTX) - MarketBeat

MarketBeat

Repare Therapeutics Inc. (NASDAQ:RPTX) Stock Holdings Lifted by BVF Inc. IL - Defense World

Defense World

Repare Therapeutics Inc. (NASDAQ:RPTX) Stock Holdings Lifted by BVF Inc. IL - MarketBeat

MarketBeat

Repare Therapeutics Inc. Expected to Earn FY2028 Earnings of $0.35 Per Share (NASDAQ:RPTX) - Defense World

Defense World

Chilton Investment Co. Inc. Invests $261000 in Vistra Corp. (NYSE:VST) - Defense World

Defense World

Repare Therapeutics Inc. (NASDAQ:RPTX) Stock Holdings Lifted by BVF Inc. IL - Defense World

Defense World

Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to ... - Business Wire

Business Wire

Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to ... - Business Wire

Business Wire

Repare doses first subject in NSCLC expansion of TRESR trial - Clinical Trials Arena

Clinical Trials Arena

We're Interested To See How Repare Therapeutics (NASDAQ:RPTX) Uses Its Cash Hoard To Grow - Yahoo New Zealand News

Yahoo New Zealand News

Repare doses first subject in NSCLC expansion of TRESR trial - Clinical Trials Arena

Clinical Trials Arena

Repare Therapeutics begins NSCLC trial expansion - Investing.com India

Investing.com India

Repare Therapeutics begins NSCLC trial expansion - Investing.com

Investing.com

Press Release Service: Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung ... - CRISPR Medicine News

CRISPR Medicine News

Repare Therapeutics begins NSCLC trial expansion By Investing.com - Investing.com UK

Investing.com UK

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of ... - StockTitan

StockTitan

Repare Therapeutics begins NSCLC trial expansion By Investing.com - Investing.com UK

Investing.com UK

RPTX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

The InvestChronicle

Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag - Yahoo Finance

Yahoo Finance

Repare Therapeutics (NASDAQ:RPTX) Given Buy Rating at HC Wainwright - Defense World

Defense World

Repare Therapeutics (NASDAQ:RPTX) Rating Reiterated by HC Wainwright - MarketBeat

MarketBeat

Press Release Service: Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in ... - CRISPR Medicine News

CRISPR Medicine News

Repare Therapeutics (NASDAQ:RPTX) Rating Reiterated by HC Wainwright - MarketBeat

MarketBeat

FDA fast tracks Repare Therapeutics ovarian cancer drug By Investing.com - Investing.com Nigeria

Investing.com Nigeria

FDA fast tracks Repare Therapeutics ovarian cancer drug By Investing.com - Investing.com

Investing.com

Repare gets FDA fast track status for ovarian cancer drug combo (NASDAQ:RPTX) - Seeking Alpha

Seeking Alpha

FDA fast tracks Repare Therapeutics ovarian cancer drug By Investing.com - Investing.com

Investing.com

Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - StockTitan

StockTitan

Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - Elk Valley Times

Elk Valley Times

Repare Therapeutics Inc. (NASDAQ:RPTX) Sees Large Decline in Short Interest - MarketBeat

MarketBeat

Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Down 23.2% in May - Defense World

Defense World

Kingspan Group (OTCMKTS:KGSPY) Trading Down 2.3% - Defense World

Defense World

Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Down 23.2% in May - Defense World

Defense World

Repare Therapeutics' (RPTX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Defense World

Repare Therapeutics' (RPTX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Defense World

Repare Therapeutics (NASDAQ:RPTX) Stock Rating Reaffirmed by HC Wainwright - MarketBeat

MarketBeat

Repare Therapeutics (NASDAQ:RPTX) Stock Rating Reaffirmed by HC Wainwright - MarketBeat

MarketBeat

Press Release Service: Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024 ... - CRISPR Medicine News

CRISPR Medicine News

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024 - Manchestertimes

Manchestertimes

Ratios in Focus: Analyzing Repare Therapeutics Inc (RPTX)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex

The Dwinnex

Jump Financial LLC Acquires Shares of 39603 Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

Defense World

Stifel analysts upgrades a Buy rating for Repare Therapeutics Inc (RPTX) – Knox Daily - Knox Daily

Knox Daily